FDA gives OK to Mesoblast for mesenchymal precursor cell production

11/20/2012 | Australian Life Scientist

Mesoblast and the FDA have reached an agreement regarding the production process for mesenchymal precursor cells to be used in late-stage clinical trials for the treatment of congestive heart failure and other conditions. The FDA and Mesoblast put in place a path for the possible commercial production of the company's cell therapy products.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC